NONALCOHOLIC FATTY LIVER DISEASE IS A CORNERSTONE OF THE CARDIOVASCULAR CONTINUUM
Downloads
Cardiovascular diseases (CVD) are the leading cause of mortality in most countries worldwide, including Uzbekistan. The main direction in preventing diseases and complications of the cardiovascular system (CVS) is the timely detection and correction of risk factors (RF). Non-alcoholic fatty liver disease (NAFLD) is considered one of the RFs of CVD development, including coronary artery disease (CAD). Data from numerous studies demonstrate increased cardiovascular risks and accelerated progression of liver pathology in the combination of NAFLD and CAD, however, some studies have not confirmed the worsening of outcomes. An association between NAFLD and CAD, atherosclerosis, cardiac rhythm disturbances, arterial hypertension, chronic heart failure and other CVDs has been identified. However, data from meta-analyses should be interpreted with caution due to the use of different diagnostic methods and the heterogeneity of studies included in them. Further studies are needed to clarify the relationship between CVDs and NAFLD further
. Eriksen C. U., Rotar O., Toft U., Jorgensen T. What is the effectiveness of systematic population-level screening programmes for reducing the burden of cardiovascular diseases? – Copenhagen: WHO Regional Office for Europe. – 2021. – 107 p.
. Материалы статистического сборника Министерства Здравоохранения Республики Узбекистан, 2020.
. 3.Смирнова М. Д. Неалкогольная жировая болезнь печени – неучтённый фактор риска атеросклероза // РМЖ. Медицинское обозрение. – 2018. − № 4. − С. 8–11.
. Селивёрстов П. В. Неалкогольная жировая болезнь печени: от теории к практике // Архивъ внутренней медицины. − 2015. − №1 (21). − C. 19-26.
. Centers for Disease Control and Prevention. Viral Hepatitis Surveillance Report – United States, 2019.
. Шаронова Л. А., Вербовой А. Ф., Вербовая Н. И., Пашенцева А. В. Взаимосвязь неалкогольной жировой болезни печени и сахарного диабета 2-го типа // РМЖ. − 2017. − №22. − С. 1635–1640.
. Le M. H., Devaki P., Ha N. B., et al. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States // PloS one. – 2017. − №12 (3), doi.org/10.1371/journal.pone.0173499.
. Сидоренко Д. В., Назаров В. Д., Лапин С. В., Эмануэль В. Л. Роль молекулярно-генетических факторов в патогенезе и диагностике неалкогольной жировой болезни печени (обзор литературы и собственные данные) // Медицинский алфавит. − 2020. − №5. − C. 13–19.
. Marchesini G., Day C. P., Dufour J., EASL-EASD-EASO Clinical Practice Guidelines for the manаgement of non-alcoholic fatty liver disease // J Hepatol. − 2016. − Vol.64 (6). − P. 1388–1402.
. Chalasani N., Bonkovsky H. L., Fontana R., et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases // Hepatology. – 2018. − №67 (1). – P. 328-357.
. Ивашкин В. Т., Маевская М. В., Павлов Ч. С., соавт. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни печени Российского общества по изучению печени и Российской гастроэнтерологической ассоциации // Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. – 2016. − №26 (2). – С. 24-42.
. Younossi Z. M., Koenig A. B., Abdelatif D., et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes // Hepatology. – 2016. − №64 (1). – P. 73–84.
. Summary Health Statistics Tables for U.S. Adults: National Health Interview Survey, 2018.
. Souveek M., Arka D., Abhijit C. Epidemiology of non-alcoholic and alcoholic fatty liver diseases // Transl Gastroenterol Hepatol. – 2020. – Р. 5-16.
. Мосина Л. М., Столярова В. В., Есина М. В., соавт. Анализ вариабельности сердечного ритма у пациентов с неалкогольной жировой болезнью печени // Медицинский алфавит. –2018. – №2 (20). – С. 33-36.
. Zeb I., Li D., Budoff M. J., et al. Nonalcoholic fatty liver disease and incident cardiac events: The Multi-Ethnic Study of Atherosclerosis // J Am Coll Cardiol. – 2016. – №67. – Р. 1965–1971, doi: 10.1016/j.jacc.2016.01.070.
. Allen A. M., Therneau T. M., Larson J. J., et al. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study // Hepatology. – 2018. – №67. – Р. 1726–1762, doi: 10.1002/hep.29546.
. Targher G., Byrne C. D., Lonardo A., et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis // J Hepatol. – 2016. − №65. – P. 589–600, doi: 10.1016/j.jhep.2016.05.013.
. Kim D., Kim W. R., Kim H. J., Therneau T. M. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States // Hepatology. – 2013. − №57. – Р. 1357–1365.
. Stahl E. P., DhindsaD. S., LeeS. K., etal. Nonalcoholic Fatty Liver Disease and the Heart // Journal of the American College of Cardiology. – 2019. – №73 (8). – Р. 948-963, doi:10.1016/j.jacc.2018.11.050.
. Siddiqui M. S., Fuchs M., Idowu M. O., et al. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile // Clin Gastroenterol Hepatol. – 2015. – №13. – Р. 1000–1008.22. Sonmez A., Nikolic D., Dogru T., et al. Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease // J Clin Lipidol. – 2015. – №9. – Р. 576–582.
. 23. Corey K. E., Misdraji J., Gelrud L., etal. Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile // Lipids Health Dis. – 2014. – №13. − Р. 100, doi: 10.1186/1476-511X-13-100.
. 24. Virović-Jukić L., Stojsavljević-Shapeski S., Forgač J., etal. Non-alcoholic fatty liver disease - a procoagulant condition? // Croat Med J. – 2021. − №62 (1). – P. 25-33, doi: 10.3325/cmj.2021.62.25.
. 25. Wójcik-Cichy K., Koślińska-Berkan E., Piekarska A. The influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases // Clin Exp Hepatol. – 2018. − №4 (1). – Р. 1-6, doi:10.5114/ceh.2018.73155.
. 26. Вовк Е. И. Неалкогольная жировая болезнь печени как проатерогенное заболевание: диагностика и лечение в общей практике // Медицинское обозрение. – 2017. − №2. – С. 68-79
. 27. Sookoian S., Pirola C. J. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review // J Hepatol. – 2008. − №49. – P. 600–607.
. 28. Jaruvongvanich V., Wirunsawanya K., Sanguankeo A., Upala S. Nonalcoholic fatty liver disease is associated with coronary artery calcification: a systematic review and meta-analysis // Dig Liver Dis. – 2016. − №48. – Р. 1410–1417.
. 29. ZhouY. Y., ZhouX. D., WuS. J., etal. Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: a systematic review and metaanalysis // Hepatology Communications. – 2018. − №2. – Р. 376–468.
. 30. Chung G. E., Choi S.Y., Kim D. et al. Nonalcoholic Fatty Liver Disease as a Risk Factor of Arterial Stiffness Measured by the Cardioankle Vascular Index // Medicine (Baltimore). − 2015. − Vol.94 (12). − P. 654, doi:0.1097/MD.0000000000000654.
. 31. Chen Y., Xu M., Wang T., et al. Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease // Atherosclerosis. − 2015. − Vol.241 (1). − P. 145–150, doi: 10.1016;
. 32. Puchner S. B., Lu M. T., Mayrhofer T., et al. High-risk coronary plaque at coronary CT angiography is associated with nonalcoholic fatty liver disease, independent of coronary plaque and stenosis burden: results from the ROMICAT II trial // Radiology. – 2015. − №274. − Р. 693–701.
. 33. Luo J., Xu L., Li J., Zhao S. Nonalcoholic fatty liver disease as a potential risk factor of cardiovascular disease // Eur J Gastroenterol Hepatol. – 2015. − №27 (3). − Р. 193–202.
. 34. Hui-Hui Liu et al. Impact of Non-Alcoholic Fatty Liver Disease on Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease: A Matched Case – Control Study // Jour Clinical and Translational Gastroenterology. – 2019. – №10.
. 35. Keskin M., Hayiroglu M. I., Uzun A. O., etal. Effect of nonalcoholic fatty liver disease on in-hospital and long-term outcomes in patients with ST-segment elevation myocardial infarction // Am J Cardiol. – 2017. − №120. – Р. 1720–1726.
. 36. Emre A., Terzi S., Celiker E., et al. Impact of nonalcoholic fatty liver disease on myocardial perfusion in nondiabetic patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction // Am J Cardiol. – 2015. − №116. − Р. 1810–1814.
. 37. Еганян Р. А. Роль неалкогольной жировой болезни печени в развитии сердечно-сосудистых заболеваний // Кардиосоматика. – 2018. − №1. С. 47-53.
. 38. Собирова Г. Н. Оптимизация патогенетической терапии неалкогольной жировой болезни печени с учетом метаболических, генетических и функциональных изменений (афтореферат). – Ташкент. – 2017. – 65 с.
. 39. Cazac G.D.; L ˘ac ˘atusu, C.M.; Mihai C.; Grigorescu E.D.; Onofriescu A.; Mihai B.M. New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis // Life. - 2022. - №12. – Р. 1189-1201. https://doi.org/ 10.3390/life12081189.
. 40. Сердюков Д., Гордиенко А. В., Сергеев А. И. Неалкогольная жировая болезнь печени и ишемическая болезнь сердца: общность патогенеза, сочетание, взаимоотягощение // Lambert Academic Publishing. – 2012. – 62 c. 41. Mauricio Montemezzo, Ahmed AlTurki, Fabio Stahlschmidt et al. Nonalcoholic Fatty Liver Disease and Coronary Artery Disease: Big Brothers in Patients with Acute Coronary Syndrome // The Scientific World Journal. - 2020. - №10. – P. 1155-1165.
. 41. Mauricio Montemezzo, Ahmed AlTurki, Fabio Stahlschmidt et al. Nonalcoholic Fatty Liver Disease and Coronary Artery Disease: Big Brothers in Patients with Acute Coronary Syndrome // The Scientific World Journal. - 2020. - №10. – P. 1155-1165.
. 42. Gofton C, Upendran Y, Zheng MH, George J. MAFLD: How is it different from NAFLD? // Clin Mol Hepatol. - 2023 - 29(Suppl). – P. 17-31.
Copyright (c) 2024 Yusupalieva D. B., Nizamov U. I., Shukurjanova S.M., Nurillaeva N. M., Shek A. B.
This work is licensed under a Creative Commons Attribution 4.0 International License.
